Early evaluation of the apoptotic index ratio is useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell carcinoma

Sobajima,Jun; Kumamoto,Kensuke; Haga,Norihiro; Tamaru,Junichi; Takahashi,Takeo; Miyazaki,Tatsuya; Ishida,Hideyuki

doi:10.3892/ol.2011.468

Early evaluation of the apoptotic index ratio is useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell carcinoma

Authors:
- Jun Sobajima
- Kensuke Kumamoto
- Norihiro Haga
- Junichi Tamaru
- Takeo Takahashi
- Tatsuya Miyazaki
- Hideyuki Ishida
View Affiliations

Affiliations: Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan, Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan, Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan, Department of General Surgical Science, Gunma University Graduate School, Graduate School of Medicine, Gunma, Japan
Published online on: November 2, 2011 https://doi.org/10.3892/ol.2011.468
Pages: 287-292

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoradiotherapy for advanced esophageal cancer is a standard treatment alongside surgical treatment. Although numerous investigators have attempted to identify the predictive markers for chemoradiosensitivity, there appear to be few candidates that can be applied in clinical use. Using biopsy specimens, we investigated the apoptotic index (AI) prior to treatment and following a radiation dose of 10 Gy to detect the early response to chemoradiotherapy in 28 patients with esophageal squamous cell carcinoma. Molecular markers, including p53, p21, bax, bcl-2, HSP27, HSP70, HSP90, Ku70, Ku86 and HIF-1α, were also examined by immunohistochemical staining. The patients were divided into two groups depending on the response to chemoradiotherapy: a responder group (RG) (n=19) that included the patients with complete or partial response, and a non-responder group (NRG) (n=9), that included patients with stable or progressive disease. In the RG and NRG, the AI of pretreatment was 4.7±5.3 (mean ± SD, cells/1,000 cells) and 5.9±3.7, respectively. The apoptotic index ratio (AIR), which was determined by dividing the AI following 10 Gy radiation by the pretreatment AI, was higher in the RG compared to the NRG (4.7±4.5 versus 1.9±1.4, p=0.03). When the cut-off value of AIR was set at 2.4, the sensitivity, specificity and accuracy were 74, 78 and 76%, respectively. Among the molecular markers we examined immunohistochemically, a positive p53 expression in the pretreatment evaluation was associated with the efficacy of chemoradiotherapy (p=0.08). Regarding the expression of other molecular markers, no significant correlations were found in RG and NRG. In the present study, the results indicated that AIR is useful for the prediction of chemoradiosensitivity in esophageal squamous cell carcinoma.

View Figures

View References

1	Greer SE, Goodney PP, Sutton JE and Birkmeyer JD: Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery. 137:172–177. 2005. View Article : Google Scholar : PubMed/NCBI
2	Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A and Cammà C: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut. 53:925–930. 2004. View Article : Google Scholar : PubMed/NCBI
3	Urschel JD and Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 185:538–543. 2003. View Article : Google Scholar
4	Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lv J, Cao XF, Zhu B, Ji L, Tao L and Wang DD: Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol. 15:4962–4968. 2009. View Article : Google Scholar : PubMed/NCBI
6	Theisen J, Krause B, Peschel C, Schmid R, Geinitz H and Friess H: Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer. World J Gastrointest Surg. 1:30–37. 2009. View Article : Google Scholar : PubMed/NCBI
7	Muro K, Ohtsu A, Boku N, Chin K, Oda Y, Fujii T, Hosokawa K, Yoshida S and Hasebe T: Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol. 26:65–69. 1996. View Article : Google Scholar : PubMed/NCBI
8	Shimoyama S, Konishi T, Kawahara M, Aoki F, Harada N, Shimizu S, Murakami T and Kaminishi M: Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer. Hepatogastroenterology. 45:1497–1504. 1998.PubMed/NCBI
9	Kitamura K, Saeki H, Kawaguchi H, Araki K, Ohno S, Kuwano H, Maehara Y and Sugimachi K: Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology. 47:419–423. 2000.PubMed/NCBI
10	Shimoji H, Miyazato H, Nakachi A, Kuniyoshi S, Isa T, Shiraishi M, Muto Y and Toda T: Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus. 13:185–190. 2000. View Article : Google Scholar : PubMed/NCBI
11	Jego G, Hazoumé A, Seigneuric R and Garrido C: Targeting heat shock proteins in cancer. Cancer Lett. 13 November;2010.(E-pub ahead of print).
12	Gullo C, Au M, Feng G and Teoh G: The biology of Ku and its potential oncogenic role in cancer. Biochim Biophys Acta. 1765:223–234. 2006.PubMed/NCBI
13	Hefferin ML and Tomkinson AE: Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst). 4:639–648. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Fukai Y, Sakurai H and Kuwano H: Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer. 110:838–844. 2004. View Article : Google Scholar : PubMed/NCBI
15	Sobin LH and Wittekind C: TNM Classification of Malignant Tumours: Sixth edition. Wiley-Liss; New York, NY: pp. 72–76. 2002
16	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
17	Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, ninth edition: Preface, general principles, part I. Esophagus. 1:61–88. 2004.
18	Japan Esophageal Society. Japanese Classification of Esophageal Cancer. 10th ed. Kanehara, Tokyo: 2007
19	Oka K, Suzuki Y and Nakano T: High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma. Cancer. 89:1526–1531. 2000. View Article : Google Scholar : PubMed/NCBI
20	Valente G, Orecchia R, Gandolfo S, Arnaudo M, Ragona R, Kerim S and Palestro G: Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? J Clin Pathol. 47:109–112. 1994. View Article : Google Scholar : PubMed/NCBI
21	Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA and Milas L: Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol. 80:185–191. 2006. View Article : Google Scholar : PubMed/NCBI
22	Mitsuhashi N, Takahashi T, Sakurai H, Nozaki M, Akimoto T, Hasegawa M, Saito Y, Matsumoto H, Higuchi K, Maebayashi K and Niibe H: A radioresistant variant cell line, NMT-1R, isolated from a radiosensitive rat yolk sac tumour cell line, NMT-1: differences of early radiation-induced morphological changes, especially apoptosis. Int J Radiat Biol. 69:329–336. 1996. View Article : Google Scholar
23	Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, Yamamoto H, Nishioka K, Kishi K and Monden M: CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 6:4859–4865. 2000.PubMed/NCBI
24	Matsubara H, Kimura M, Sugaya M, Koide Y, Gunji Y, Takegana K, Asano T, Ochiai T, Isono K, Sakiyama S and Tagawa M: Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells. Int J Oncol. 14:1081–1085. 1999.PubMed/NCBI
25	Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, Kitahara T and Mitamura K: Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol. 36:303–311. 2001. View Article : Google Scholar : PubMed/NCBI
26	Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R and Gabbert HE: p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 74:2218–2223. 1994. View Article : Google Scholar : PubMed/NCBI